New Release
Cutaneous Toxicities from Anticancer Therapies
Edition:
1
ISBN/ISSN:
9781975157890
Publication Date:
February 15, 2023
2023-02-15
9781975157890
Many oncologic therapies used to treat cancer have significant implications for the skin. These dermatologic reactions follow recognizable patterns and ...
Read More
-
-
Many oncologic therapies used to treat cancer have significant implications for the skin. These dermatologic reactions follow recognizable patterns and are closely related to the type of treatment given. Cutaneous Toxicities from Anti-Cancer Therapies,by Drs. Allireza Alloo and Nicole LeBoeuf, provides comprehensive coverage of cutaneous toxicities caused by the full spectrum of oncologic modes of treatment—specifically cytotoxic chemotherapy, targeted chemotherapy, and immunotherapy. This portable photoguide is a quick bedside handbook for dermatologists, oncologists, primary care providers, emergency room physicians, and other health care professionals who see patients undergoing treatment for cancer.
Summarizes current evidence on skin toxicity from oncologic treatment using a succinct, highly practical format for quick reference
Defines specific reaction patterns for oncology therapies and provides clinical pearls and treatment recommendations
Features abundant full-color clinical photos that help you quickly identify reaction patterns and skin toxicity from specific cancer therapies
Highlights special considerations for skin of color and pediatrics in boxes throughout the book
Enrich Your eBook Reading Experience
Read directly on your preferred device(s),such as computer, tablet, or smartphone.
Easily convert to audiobook,powering your content with natural language text-to-speech.
-
Edition1ISBN/ISSN9781975157890Product FormatPaperback BookTrim Size6 x 9Pages312Edition1Publication DateFebruary 15, 2023Weight1.05
-
- Nicole LeBoeuf
- Allireza Alloo
-
CONTENTS
Contributors vi
oreword xi
Introduction xii
Part I: Special Considerations
1. Reactions in Patients with Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2. Reactions in Pediatric Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Part II: Reaction Patterns
3. Morbilliform Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
4. Lichenoid Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
5. Psoriasiform Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
6. Acneiform Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
7. Intertriginous Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
8. Bullous Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
9. P anniculitis- Lik e Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
10. Purpuric Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
11. Erythroderma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
12. Edematous Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
13. Sclerosing Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
14. Pigmentary Alterations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
15. Reactions on the Hands and Feet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
16. Oral Toxicities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
17. Mucositis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
18. Hair and Nail Abnormalities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
19. Radiation Recall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
20. Inflamed Actinic Keratoses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
21. Severe Cutaneous Adverse Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
Part III: Anticancer Agents and Classes
Section I: Cytotoxic Chemotherapy
22. Alkylating Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
23. Antimetabolites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
24. Topoisomerase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
25. Anthracyclines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
26. Microtubule Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
27. Bleomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141Section II: Targeted Agents
28. Epidermal Growth Factor Receptor (EGFR) Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
29. BRAF Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
30. MEK Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
31. PI3- Kinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
32. mTOR Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .170
33. Multikinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
34. BTK Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
35. BCR/ABL/C- Kit Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
36. Fibroblast Growth Factor Receptor (FGFR) Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
37. Proteasome Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
38. Hormonal Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
39. CCR4 Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
Section III: Immunotherapy and Immune Modulators
40. Cytotoxic T- Lymphocyte- Associated Protein 4 (CTLA-4) Inhibitors . . . . . . . . . . . . . . . . . 209
41. Programmed Cell Death 1 (PD- 1)/Programmed Cell Death Ligand 1 (PD- L1)
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214
42. Thalidomide and Lenalidomide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
Part IV: Other Anticancer Treatment–Associated Toxicities
43. Radiation Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
44. Pruritus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235
Appendix 245
Photo Credits 251
Index 253
USD $79.99
IN STOCK
Quantity:
Buy from another retailer
Added To Your Cart
Cutaneous Toxicities from Anticancer Therapies
ISBN/ISSN: 9781975157890
Quantity :
Recommended For You
YOU MIGHT ALSO LIKE
